AI Terminal
Elos Medtech
Delisting Announcement • Nov 21, 2023
3039_iss_2023-11-21_5e192aa2-25cd-4c92-a629-5813947855ee.pdf
Delisting Announcement
Open in ViewerOpens in native device viewer
Elos Medtech applies for de-listing from Nasdaq Stockholm
The board of directors of Elos Medtech has today resolved to apply for de-listing of the Company's shares from Nasdaq Stockholm as a result of TA Associates, through EM Intressenter AB ("EM Intressenter"), controlling more than 90 percent of the shares in Elos Medtech AB (publ) ("Elos Medtech" or the "Company"), today having initiated compulsory redemption of the remaining shares in the Company.
EM Intressenter has informed the board of directors of Elos Medtech that EM Intressenter initiates compulsory redemption of the remaining shares in Elos Medtech and requested that the shares in Elos Medtech are de-listed from Nasdaq Stockholm.
In light of the above, and in accordance with EM Intressenter's request, the board of directors of Elos Medtech has resolved to apply for de-listing of the Company's shares from Nasdaq Stockholm. The last day of trading in Elos Medtech's shares on Nasdaq Stockholm will be announced as soon as Elos Medtech has received confirmation thereof from Nasdaq Stockholm.
For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342, email: [email protected] Magnus René, Chairman of the Board, +1 781 266 6957, email: [email protected]
About Elos Medtech
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The Company operates from facilities in Sweden, Denmark, China, and the U.S. The customer base comprises international medical technology companies.
Elos Medtech has more than 650 employees and a turnover of approximately SEK 950 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech's B share is categorized as a Health Care company on the Mid Cap list.
This is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on November 21st , 2023, at 20:30 (CET)